Market closed
Context Therapeutics/$CNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Ticker
$CNTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
12
Website
CNTX Metrics
BasicAdvanced
$78M
-
-$0.46
2.06
-
Price and volume
Market cap
$78M
Beta
2.06
52-week high
$1.04
52-week low
$0.55
Average daily volume
213K
Financial strength
Current ratio
35.619
Quick ratio
34.358
Long term debt to equity
0.118
Total debt to equity
0.23
Management effectiveness
Return on assets (TTM)
-32.76%
Return on equity (TTM)
-49.89%
Valuation
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-1.733
Growth
Earnings per share change (TTM)
-69.52%
3-year earnings per share growth (CAGR)
-50.14%
CNTX News
AllArticlesVideos
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewsWire·4 days ago
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
GlobeNewsWire·4 weeks ago
Context Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Context Therapeutics stock?
Context Therapeutics (CNTX) has a market cap of $78M as of May 04, 2025.
What is the P/E ratio for Context Therapeutics stock?
The price to earnings (P/E) ratio for Context Therapeutics (CNTX) stock is 0 as of May 04, 2025.
Does Context Therapeutics stock pay dividends?
No, Context Therapeutics (CNTX) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Context Therapeutics dividend payment date?
Context Therapeutics (CNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Context Therapeutics?
Context Therapeutics (CNTX) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.